// App-Quantinova.ai

2992 : Duration of Response to Luspatercept in Patients (Pts) Requiring Red Blood Cell (RBC) Transfusions with Myelofibrosis (MF) – Updated Data from the Phase 2 ACE-536-MF-001 Study

Researchers

Presenter

  • Aaron T. Gerds

Principal Investigators

  • Francesco Passamonti

  • Marina Kremyanskaya

  • Jason Gotlib

  • Jeanne M. Palmer

  • Kelly McCaul

  • Vincent Ribrag

  • Adam J. Mead

  • Claire Harrison

  • Ruben Mesa

  • Jean-Jacques Kiladjian

  • Giovanni Barosi

  • Torsten G. Gerike

  • Jeevan K. Shetty

  • Joseph Pariseau

  • Gabriel Miranda

  • Martin Schwickart

  • Ana Carolina Giuseppi

  • Jennie Zhang

  • Jay T. Backstrom

  • Srdan Verstovsek

Medical Centers

  • Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

  • Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, Florence, Italy

  • Department of Medicine and Surgery, University of Insubria, Varese, Italy

  • Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai / The Tisch Cancer Institute, New York, NY

  • Stanford University Cancer Institute, Stanford, CA

  • Division of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ

  • Avera Cancer Institute, Sioux Falls, SD

  • Institut Gustave-Roussy, Villejuif, France

  • Oxford University Hospitals NHS Trust, Oxford, United Kingdom

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Mays Cancer Center, UT Health San Antonio, San Antonio, TX, USA

  • Hopital Saint-Louis and Universite Paris Diderot, Paris, France

  • IRCCS Policlinico San Matteo, Pavia, Italy

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Celgene International Sàrl, a Bristol Myers Squibb Company, Boudry, Switzerland

  • Acceleron Pharma, Cambridge, MA

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

Locations

  • United States

  • Italy

  • France

  • United Kingdom

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Myelofibrosis

  • Anemia

Biomarkers

  • N/A

Drug/Treatment

  • luspatercept

  • Ruxolitinib phosphate

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved